ABP 215 (MVASI™, Amgen, Thousand Oaks, CA; MVASI™, Amgen Europe B.V., Netherlands) is a biosimilar to bevacizumab (Avastin®, Genentech, South San Francisco, CA) reference product (RP), a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) [1, 2]. Bevacizumab binds to VEGF-A and inhibits its binding to, and activation of, its receptors on the exterior of endothelial cells, thereby interfering with angiogenesis and various downstream oncogenic pathways [3, 4] (Fig. 1) (Video: MOA).
Supplementary file Animated mechanism of action video (MP4 6205 KB)
ABP 215 is approved in the United States (US) and the European Union (EU) for metastatic colorectal cancer; unresectable, locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer (NSCLC); metastatic renal cell carcinoma; and persistent, recurrent, and metastatic cervical cancer. Additionally, ABP 215 is approved in the EU for metastatic breast cancer; non-squamous NSCLC with epidermal growth factor-activating mutations (in combination with erlotinib); and advanced/recurrent epithelial ovarian and fallopian cancer; and in the US for recurrent glioblastoma in adults [1,2,3].
Biosimilars are similar versions of originator biologics. Biologics are complex molecules that are manufactured using living cells and used in the treatment of several chronic inflammatory diseases and cancer. Access to biologics is limited, and the availability of biosimilars has the potential to provide additional biologic drug options [5, 6].
Unlike generic drugs, which are chemically synthesized and identical to their RPs, a biosimilar is structurally and functionally similar to its RP while showing no clinically meaningful differences in safety, purity, or potency [5, 7,8,9,10,11,12]. The biological characteristics of the cell lines used in their production and the complexity of manufacturing processes may impact the composition, structure, and stability of the biosimilar [13]. As a result, a biosimilar is both distinct from and similar to its RP.
The development of a biosimilar requires extensive, scientifically rigorous, comparative assessments and evaluations. The body of nonclinical, preclinical, and clinical data obtained to demonstrate the similarity of a proposed biosimilar to its RP is referred to as the “totality of evidence” (TOE) and forms the basis for its regulatory approval [5].
This article will provide a brief overview of the TOE for ABP 215 as a biosimilar to bevacizumab RP (Fig. 2) and will discuss practical considerations related to its storage and clinical use. The article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
Totality of Evidence for ABP 215
As the first step in the development of ABP 215, comprehensive, state-of-the-art analytical assessments were performed to identify any potential structural and functional differences between ABP 215 and bevacizumab RP. For these assessments, the RP was sourced from the US (bevacizumab US) and the EU (bevacizumab EU). ABP 215 and bevacizumab RP had similar primary structure (including polypeptide composition and glycosylation), secondary (higher-order) structure, and process-related substances and impurities [14]. Thermal stability, degradation rates, and general properties (protein concentration, volume, osmolality, pH, appearance, color, and clarity) were also similar for ABP 215 and the bevacizumab RPs [14].
The biological and functional properties of ABP 215 and bevacizumab RP were also shown to be similar, as evidenced by similar relative target binding affinity to VEGF-A and in vitro potency for preventing VEGF binding to its receptor (as seen by inhibition of VEGF receptor signaling of tyrosine kinase activity). Furthermore, ABP 215 and bevacizumab RP had similar potency for inhibiting vascular growth in vitro, as demonstrated by similarity in proliferation of human umbilical vein endothelial cells. These findings indicate that ABP 215 and the RP have the same mechanism of action (MOA).
The next step in biosimilar development is the evaluation of clinical pharmacology. The pharmacokinetics (PK) of ABP 215 were assessed in a randomized, single-blind, single-dose, three-arm, parallel-group study in healthy subjects. Study findings confirmed the similarity between PK parameters of ABP 215 and bevacizumab RP [15]. A separate PK study conducted in healthy adult Japanese male subjects also showed similarity in PK parameters for ABP 215 and bevacizumab RP; results were similar to those reported in the global study [16]. Within each study, safety and tolerability findings were comparable for ABP 215 and the RP, with similar incidence of treatment-emergent adverse events (AEs) of all grades. No subjects in these studies developed binding or neutralizing anti-drug antibodies (ADAs) [15, 16].
As the final step in the development of biosimilars to complete the TOE, a comparative clinical study was conducted using a single comparator. The efficacy and safety of ABP 215 compared with bevacizumab RP were evaluated in a randomized, double-blind, active-controlled, multicenter, multinational study (MAPLE), which enrolled adult patients with stage IV or recurrent non-squamous NSCLC receiving first-line carboplatin and paclitaxel [17]. This patient population is considered to be sensitive and well-characterized, with fewer potential confounding factors, thus suitable for comparison of a bevacizumab biosimilar to the RP [18, 19].
A total of 642 patients were randomized to receive ABP 215 (n = 328) or bevacizumab RP (n = 314) 15 mg/kg every three weeks for six cycles along with carboplatin and paclitaxel every three weeks for ≥ 4 cycles and ≤ 6 cycles, respectively. The primary efficacy endpoint was the risk ratio of the objective response rate (ORR), which was defined as the rate of best overall response of either complete response or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Responses were assessed by blinded, central, independent radiologists who reviewed radiographic images in the intent-to-treat population [17]. Objective responses were observed in 128 (39%) patients receiving ABP 215 and 131 (41.7%) receiving bevacizumab RP. The risk ratio for the ORR was 0.93 [90% confidence interval (CI), 0.80–1.09]. The two-sided CI for the ORR fell within the prespecified margin for equivalence of 0.67–1.5, indicating similar clinical efficacy (Fig. 3) [17].
The overall type, severity, and frequency of AEs (Table 1) and AEs of interest were comparable for the ABP 215 and bevacizumab RP groups. The incidence of grade ≥ 3 AEs of interest for the ABP 215 and bevacizumab RP groups, respectively, were hypertension (22 patients, 6.8%; 17 patients, 5.5%), gastrointestinal perforation (three patients, 0.9%; four patients, 1.3%), pulmonary hemorrhage (two patients, 0.6%; five patients, 1.6%), wound-healing complications (one patient, 0.3%; two patients, 0.6%), and proteinuria (one patient, 0.3%; one patient, 0.3%) [17]. The frequency of immunogenicity was similarly low for the two treatment groups. A total of four (1.4%) patients in the ABP 215 and seven patients (2.5%) in the bevacizumab RP arm developed binding ADAs, and for three patients (1.0% for ABP 215 and 1.1% for bevacizumab RP) in each arm, binding antibodies were transient (i.e., results were negative at the last study assessment). No patient had a positive finding for neutralizing antibodies [17].
Table 1 Safety findings in the comparative clinical trial of ABP 215 and bevacizumab (MAPLE) [17] The nonclinical, preclinical, and clinical results reviewed here comprise the TOE that provides robust evidence that ABP 215 is highly similar to bevacizumab RP and has similar safety and efficacy in stage IV NSCLC [3].
Extrapolation of Indications for ABP 215
Extrapolation of indications is a unique component of regulatory approval of biosimilars. In this context, extrapolation refers to approval of the biosimilar for all of the indications for which the RP is approved except those protected by regulatory exclusivities. Justification for extrapolation is supported by all of the known factors that could affect safety or effectiveness in each indication [3, 17, 20, 21].
Specific findings from the TOE for the similarity of ABP 215 and bevacizumab RP support the extrapolation of its indications to all indications for which the bevacizumab RP is approved [1,2,3, 20]. The comprehensive analytical similarity assessment showed similarity between these two agents, which included similarity in the MOA [14]. The PK profiles for ABP 215 and bevacizumab RP were similar in healthy subjects [15, 16] as well as in patients with NSCLC [3, 17]. PK parameters for bevacizumab RP have been previously shown to be consistent across patients with different tumor types (e.g., NSCLC, colorectal cancer, metastatic breast cancer, etc.) [20]. These data provide justification supporting extrapolation for use of ABP 215 in all approved indications of the RP. The similarity of immunogenicity observations for ABP 215 and bevacizumab RP suggest that similar immunogenicity profiles may be expected for ABP 215 in all patient populations. The similar safety and efficacy profiles of ABP 215 and bevacizumab RP, also resembling those previously seen with bevacizumab RP, are supportive of similar safety and efficacy for ABP 215 when used for other indications. Furthermore, the similar safety and efficacy profiles for ABP 215 and bevacizumab RP for subgroups of patients with advanced NSCLC provide predictive data for safety and efficacy in other indications in which there is potential for PK interactions with chemotherapeutic therapies and other potential complications.
Stability and Clinical Use of ABP 215
As with bevacizumab RP, ABP 215 is supplied as a sterile solution in a single-use vial (100 mg/4 mL or 400 mg/16 mL). Similar to bevacizumab RP, ABP 215 should be administered intravenously in an infusion bag after appropriate dilution. The protocol for the correct method for storage and preparation of ABP 215 for administration is provided in Table 2.
Table 2 The protocol for storage and preparation of ABP 215 [1, 2] Preparation of ABP 215 product in some regions may be performed at oncology sites or at central pharmacy locations and then distributed to clinical oncology sites for administration. Therefore, it is important to understand the stability of ABP 215 under the conditions of use; the physicochemical stability of ABP 215 under in-use conditions was therefore assessed [22]. Infusion bags containing formulation buffer, ABP 215 1.4 mg/mL, and 16.5 mg/mL were prepared and stored at 2–8 °C for 35 days followed by storage at 30 °C for 48 h. No meaningful changes were seen in results from three purity assays. Protein recovery following the study storage periods in the intravenous bag and infusion system ranged from 99.4% to 101.7%, indicating no protein (product) loss (Fig. 4a). Results from assays for inhibition of human umbilical vein epithelial cell proliferation indicated no notable loss in potency (Fig. 4b). Visual inspection revealed no potentially proteinaceous particles, and no trends were found for subvisible particulate matter in the drug product and control formulation buffer.